Form D · Venture Capital Fund

Frazier Life Sciences VIII, L.P.

Seattle, WA · CIK 0001655827

Offering snapshot reported Oct 29, 2015 · SEC filing

Reported sold: $262M
Investors reported: 46
Minimum accepted: $68.8K
First sale: Oct 15, 2015

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 29, 2015	Initial	$262,000,000	No comparison	46	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.1, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-250272

Total Offering Amount and Total Amount Sold are inclusive of the General Partner's $12,000,000 commitment to the Issuer.

Source: Form D, filed Oct 29, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

FRAZIER LIFE SCIENCES VIII, L.P.

Investment adviser: FRAZIER LIFE SCIENCES MANAGEMENT, LP

Gross asset value: $260M
Beneficial owners: 50
ADV minimum commitment: $3M

Reported in Form ADV on Mar 31, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Auditor DELOITTE & TOUCHE LLP SEATTLE, Washington, United States

Custodian EQUINITI TRUST COMPANY, LLC MENDOTA HEIGHTS, Minnesota, United States Related to adviser: No

Custodian JEFFERIES LLC NEW YORK, New York, United States Related to adviser: No

Custodian JPMORGAN CHASE & CO NEW YORK, New York, United States Related to adviser: No

Custodian SILICON VALLEY BANK SANTA CLARA, California, United States Related to adviser: No

Prime broker JEFFERIES LLC NEW YORK, New York, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: No
External marketing: No

DELOITTE & TOUCHE LLP
PCAOB 34

JEFFERIES LLC
SEC 8-15074

JEFFERIES LLC
CRD 2347 · SEC 8-15074

Filing source

Form ADV 2059529 · Mar 31, 2026 · Schedule D 7.B.(1), fund 805-8591061248

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Related funds

Funds whose names form a numbered series with this one and that share its city or the name of a related person. Form D does not state how these funds are related.

Fund	Latest Form D	Reported sold	Investors
Frazier Life Sciences VIII, L.P. (this fund)	Oct 29, 2015	$262,000,000	46
Frazier Life Sciences IX, L.P.	Nov 1, 2017	$418,925,000	55
Frazier Life Sciences X, L.P.	Dec 17, 2019	Yet to sell	0
Frazier Life Sciences XI, L.P.	Mar 18, 2022	$960,000,000	98
Frazier Life Sciences XII, L.P.	Mar 17, 2025	Yet to sell	0

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Nathan Every	Promoter
N/A Fhm Life Sciences Viii, L.L.C.	Executive
N/A Fhm Life Sciences Viii, L.P.	Executive
Alan D. Frazier	Promoter
N/A Frazier Management, L.L.C.	Promoter
Patrick J. Heron	Executive
Nader Naini	Promoter
James N. Topper	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

601 Union Street Suite 3200
Seattle, WA, 98101